hMSH2在子宫内膜良恶性病变中的表达及其临床意义

Expression and Clinical Significance of hMSH2 in the Benign and Malignant Diseases of Endometrium

目的:检测hMSH2基因在人子宫内膜良恶性病变组织中的表达及其与子宫内膜癌临床病理特征的关系。方法:应用免疫组织化学法检测20例子宫内膜腺癌,10例子宫内膜单纯性增生过长组织中错配修复基因hMSH2蛋白的表达。结果:子宫内膜单纯性增生hMSH2蛋白表达的阳性率为90%(9/10),明显高于子宫内膜癌的55%(11/20),差异具显著性(P<0.05);在20例子宫内膜癌中,中、高分化者hMSH2蛋白阳性率为66.7%(8/12),低分化者为37.5% (3/8),二者相比,差异无显著性(P=0.362);HGO分期Ⅰ～Ⅱ期阳性率为63.6%(7/11),Ⅲ～Ⅳ期为44.4%(4/9),二者差异无显著性(P=0.653)。结论:hMSH2基因突变与子宫内膜腺癌的发生有关,与子宫内膜腺癌的临床期别无关,与病理分化程度有关。hMSH2蛋白的检测可能有助于子宫内膜癌的早期诊断及判断预后。

Objective： To detect the expression and clinical significance of hMSH2 gene in the tissues of benign and malignant diseases of human endometrium, and the association with the clinical pathological characteristics of endometrial cancer. Methods： The expression of hMSH2 （ the mismatch repair gene） in the tissues of endometrial cancer （ n = 20 ） and simple hyperplasia of endometrium （n = 10） were detected with immunohistochemical method. Results： The positive rate of hMSH2 protein expression in the simple hyperplasia of endometrium group （90%, 9/10 ） was significantly higher than that in endometrial cancer （55%, 11/20） （ P 〈 0.05 ）. In the 20 cases of endometrial cancer, the positive rate of hMSH2 protein expression had no significant difference between the patients with moderate and high differentiation （66. 7%, 8/12 ） and those with low differentiation （37.5%, 3/8 ） （ P 〉 0.05 ）, also between the patients of international Federation of Gynecology and Obstetrics （ FIGO） grades Ⅰ - Ⅱ （63.6%, 7/11） and those of grades Ⅲ - Ⅳ （44.4%, 4/9） （P〉0.05）. Conclusion： The hMSH2 gene mutation is associated with the occurrence and the severity of pathological differentiation of endometrial cancer, but not with its clinical stage. The detection of hMSH2 protein may be helpful for the early diagnosis and prognostic judgement of endometrial cancer.